地西他滨联合化疗治疗难治复发急性髓系白血病及骨髓增生异常综合征转化白血病的效果观察

被引：14

作者：

韩波 ^{[1
]}

王朝晖 ^{[1
]}

邵纬 ^{[2
]}

王九河 ^{[1
]}

洪青 ^{[1
]}

范传波 ^{[1
]}

刘俊玲 ^{[1
]}

田猛 ^{[1
]}

王海霞 ^{[1
]}

乌庆超 ^{[1
]}

机构：

[1] 青岛海慈医疗集团血液科

[2] 青岛海慈医疗集团肿瘤科

来源：

白血病·淋巴瘤 | 2014年 / 23卷 / 12期

关键词：

白血病,髓样,急性; 骨髓增生异常综合征转化白血病; 难治; 复发; 地西他滨药物疗法;

D O I：

暂无

中图分类号：

R733.71 [急性白血病];

学科分类号：

100214 [肿瘤学];

摘要：

目的探讨地西他滨联合化疗治疗难治复发急性髓系白血病（AML）及骨髓增生异常综合征（MDS）转化AML的临床效果。方法选取2013年2月至2014年3月住院治疗的难治复发AML患者19例及MDS转化AML患者4例,所有患者给予地西他滨联合CAG方案进行治疗,评估患者治疗效果及不良反应。结果经过1个疗程治疗后,14例（60.9%）完全缓解,2例（8.7%）部分缓解,7例（30.4%）无效,总有效率69.6%,不同染色体核型患者临床治疗效果差异具有统计学意义（P<0.05）。23例患者出现不同程度的骨髓抑制,其中ⅠⅡ级中性粒细胞减少2例,ⅢⅣ级21例,中性粒细胞减少中位时间13 d;ⅢⅣ级贫血23例;ⅢⅣ级血小板减少23例,血小板减少中位时间16 d。ⅠⅡ级出血20例,ⅢⅣ级3例。ⅠⅡ级胃肠道反应1例。ⅠⅡ级肝功能异常1例。所有患者随访至2014年3月31日,生存20例,死亡3例,中位总生存期3.1个月,1年累积生存率86%。结论地西他滨联合化疗治疗难治复发AML及MDS转化白血病的临床缓解率高,不良反应少;染色体核型可能是影响治疗效果的重要因素。

引用

共 8 条

[1]

Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents [J].

Ferrero, Dario ;

Crisa, Elena ;

Marmont, Filippo ;

Audisio, Ernesta ;

Frairia, Chiara ;

Giai, Valentina ;

Gatti, Tiziana ;

Festuccia, Moreno ;

Bruno, Benedetto ;

Riera, Ludovica ;

Passera, Roberto ;

Boccadoro, Mario .

ANNALS OF HEMATOLOGY, 2014, 93 (08) :1391-1400

[2]

Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia [J].

Liu, Limin ;

Zhang, Yanming ;

Jin, Zhengming ;

Zhang, Xingxia ;

Zhao, Guangsheng ;

Si, Yejun ;

Lin, Guoqiang ;

Ma, Aidi ;

Sun, Yingxin ;

Wang, Li ;

Wu, Depei .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (05) :603-608

[3]

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [J].

Thomas, Xavier G. ;

Arthur, Christopher ;

Delaunay, Jacques ;

Jones, Mark ;

Berrak, Erhan ;

Kantarjian, Hagop M. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (01) :68-72

[4]

A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes [J].

Cermak, Jaroslav ;

Jonasova, Anna ;

Vondrakova, Jana ;

Cervinek, Libor ;

Belohlavkova, Petra ;

Neuwirtova, Radana .

LEUKEMIA RESEARCH, 2013, 37 (12) :1612-1615

[5]

Epigenetic action of decitabine (5-aza-2′-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C) [J].

Momparler, Richard L. ;

Cote, Sylvie ;

Momparler, Louise F. .

LEUKEMIA RESEARCH, 2013, 37 (08) :980-984

[6]

Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia [J].

Song, Lu Xi ;

Xu, Li ;

Li, Xiao ;

Chang, Chun Kang ;

Zhang, Yi ;

Wu, Ling Yun ;

He, Qi ;

Zhang, Qing Xia ;

Li, Xiang .

ANNALS OF HEMATOLOGY, 2012, 91 (12) :1879-1886

[7]

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management [J].

Garcia-Manero, Guillermo .

AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (07) :692-701

[8]

Analysis of drug resistanceassociated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology..Zeng DF;Zhang J;Zhu LD;et al;.Eur Rev Med Pharmacol Sci.2014,

← 1 →